PATENT CLAIM ANALYSIS

Application Number: 15956168
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["544", "405000"]

Abstract:
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , n, m, p and q are as defined herein, which are active as modulators of retinoid-related Sorphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

Claim (Index 58):
The method according to  claim 57 , wherein the disease, disorder, syndrome or condition is an inflammatory or autoimmune disease.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 91.0
- Lexical Diversity: 1.67089
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15318513', '15754037', '14778892', '15103658', '15182231']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7898655175515044
- 35 USC 102 Novelty (BERT): 0.5640157948928546
- Combined Prediction Score: 0.7672805452856394
- Mean Citation Score: 395.299002
- Max Citation Score: 494.7726
- Similarity Product: 308.9901956588388

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test